Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$52.82
-0.5%
$54.26
$30.04
$71.13
$4.80B1.82.61 million shs1.17 million shs
CureVac N.V. stock logo
CVAC
CureVac
$5.42
-0.6%
$5.45
$2.37
$5.72
$1.22B2.53951,137 shs609,600 shs
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
$106.30
+0.9%
$97.50
$18.71
$117.70
$94.47B2.3641.80 million shs34.48 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$26.22
-2.5%
$29.19
$23.15
$86.80
$10.20B1.8310.68 million shs5.61 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-2.01%-8.29%-18.77%+41.41%+8.15%
CureVac N.V. stock logo
CVAC
CureVac
-0.18%-0.91%+0.93%+31.01%+68.73%
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
-2.01%-3.02%+0.96%+62.64%+431.22%
Moderna, Inc. stock logo
MRNA
Moderna
-3.65%0.00%-13.17%+0.64%-69.07%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
3.7612 of 5 stars
4.33.00.00.02.73.30.6
CureVac N.V. stock logo
CVAC
CureVac
4.611 of 5 stars
4.15.00.04.91.70.01.3
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
3.8865 of 5 stars
2.35.00.00.03.94.21.9
Moderna, Inc. stock logo
MRNA
Moderna
4.3827 of 5 stars
4.02.00.04.61.92.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.50
Moderate Buy$71.6036.60% Upside
CureVac N.V. stock logo
CVAC
CureVac
2.20
Hold$6.8325.96% Upside
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
2.56
Moderate Buy$100.31-5.22% Downside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$43.5966.27% Upside

Current Analyst Ratings Breakdown

Latest MRNA, CRSP, CVAC, and HOOD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/7/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$65.00 ➝ $80.00
8/6/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$42.00 ➝ $56.00
8/5/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00
8/5/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$38.00 ➝ $42.00
8/4/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$40.00 ➝ $31.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$32.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$26.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$32.00
7/31/2025
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$99.00 ➝ $120.00
7/31/2025
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$102.00 ➝ $120.00
(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$37.31M127.77N/AN/A$18.81 per share2.79
CureVac N.V. stock logo
CVAC
CureVac
$579.18M2.10$0.87 per share6.25$2.97 per share1.83
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
$2.95B31.87$1.18 per share89.36$9.08 per share11.66
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.15N/AN/A$24.16 per share1.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$366.25M-$5.43N/AN/AN/A-1,229.43%-20.05%-17.09%11/4/2025 (Estimated)
CureVac N.V. stock logo
CVAC
CureVac
$175.50M$0.965.65N/AN/A38.21%29.57%25.41%8/21/2025 (Estimated)
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
$1.41B$1.9753.8165.333.9450.13%17.48%4.12%10/29/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)

Latest MRNA, CRSP, CVAC, and HOOD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/21/2025Q2 2025
CureVac N.V. stock logo
CVAC
CureVac
-$0.15-$0.30-$0.15-$0.30$4.27 million$1.41 million
8/4/2025Q2 2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.47-$1.29+$0.18-$2.40$6.44 million$0.89 million
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
7/30/2025Q2 2025
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
$0.30$0.42+$0.12$0.42$893.93 million$989.00 million
5/22/2025Q1 2025
CureVac N.V. stock logo
CVAC
CureVac
-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
CureVac N.V. stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A
16.61
16.61
CureVac N.V. stock logo
CVAC
CureVac
0.05
6.17
7.64
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
N/A
1.25
1.25
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77

Institutional Ownership

CompanyInstitutional Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
CureVac N.V. stock logo
CVAC
CureVac
17.26%
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
93.27%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
4.30%
CureVac N.V. stock logo
CVAC
CureVac
2.15%
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
14.47%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
46090.95 million87.04 millionOptionable
CureVac N.V. stock logo
CVAC
CureVac
880224.34 million219.52 millionOptionable
Robinhood Markets, Inc. stock logo
HOOD
Robinhood Markets
2,300888.67 million760.08 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800389.08 million346.28 millionOptionable

Recent News About These Companies

Moderna to Present at Upcoming Conferences in September 2025
Kennedy’s mRNA cuts could set US science back, experts warn
RFK risks us all in targeting mRNA vaccine research

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$52.82 -0.25 (-0.47%)
Closing price 04:00 PM Eastern
Extended Trading
$52.86 +0.04 (+0.08%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CureVac stock logo

CureVac NASDAQ:CVAC

$5.42 -0.03 (-0.55%)
Closing price 04:00 PM Eastern
Extended Trading
$5.44 +0.01 (+0.28%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Robinhood Markets stock logo

Robinhood Markets NASDAQ:HOOD

$106.30 +0.96 (+0.91%)
Closing price 04:00 PM Eastern
Extended Trading
$106.01 -0.29 (-0.27%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Robinhood Markets, Inc. operates financial services platform in the United States. Its platform allows users to invest in stocks, exchange-traded funds (ETFs), American depository receipts, options, gold, and cryptocurrencies. The company offers fractional trading, recurring investments, fully-paid securities lending, access to investing on margin, cash sweep, instant withdrawals, retirement program, around-the-clock trading, and initial public offerings participation services. It also provides various learning and education solutions comprise Snacks, an accessible digest of business news stories for a new generation of investors.; Learn, which is an online collection of beginners' guides, feature tutorials, and financial dictionary; Newsfeeds that offer access to free, premium news from sites from various sites, such as Barron's, Reuters, and Dow Jones. In addition, the company offers In-App Education, a resource that covers investing fundamentals, including why people invest, a stock market overview, and tips on how to define investing goals, as well as allows customers to understand the basics of investing before their first trade; and Crypto Learn and Earn, an educational module available to various crypto customers through Robinhood Learn to teach customers the basics related to cryptocurrency. Further, it provides Robinhood credit cards, cash card and spending accounts, and wallets. Robinhood Markets, Inc. was incorporated in 2013 and is headquartered in Menlo Park, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$26.22 -0.67 (-2.49%)
Closing price 04:00 PM Eastern
Extended Trading
$26.26 +0.04 (+0.15%)
As of 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.